Efficacy of Second-Line Lenvatinib After Atezolizumab-Bevacizumab and Durvalumab-Tremelimumab in Unresectable Hepatocellular Carcinoma: Association with Prior Immunotherapy Response.

Cancers (Basel) · 2026 · PMC13359612 · PMID 42449639

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

The Dur/Tre group showed numerically lower disease control rates and shorter prior ICI PFS than the Atz/Bev group, although these differences did not reach statistical significance. 3.2.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.